"TLD1433, a Ru (II) polypyridyl complexes, is a novel photosensitizer for PDT with photochemical and photophysical properties to provide energy and electron transfer, resulting in oxygen-dependent and/or oxygen-free photobiological activity. The effectiveness and safety of TLD1433 for NMIBC treatment were confirmed in a phase 1 trial." This article is a very readable summary of current and prospective bladder cancer solutions. The full text is available at this link:
Advances in Diagnosis and Therapy for Bladder Cancer Xinzi Hu 1,2,Guangzhi Li 1,2 and Song Wu 1,2 1 Institute of Urology, The Affiliated Luohu Hospital of Shenzhen University, Shenzhen University, Shenzhen 518000, China
2 Department of Urology, South China Hospital, Health Science Center, Shenzhen University, Shenzhen 518116, China
These authors contributed equally to this work.
Academic Editor: Alchiede Simonato
Cancers 2022, 14(13), 3181; https://doi.org/10.3390/cancers14133181
Received: 24 May 2022 / Revised: 19 June 2022 / Accepted: 24 June 2022 / Published: 29 June 2022
Simple Summary
The clinical management of bladder cancer has been developing in the past decade, including diagnostic tools and treatment options. Both monotherapy and combination therapy have been undoubtedly upgraded. Multiple diagnostic techniques and therapeutic strategies have been developed to meet the urgent clinical needs, resulting in the emergence of various explorations for cancer diagnosis and therapy. In this review, we mainly focus on the advances in the diagnosis and treatment of bladder cancer.
Abstract
Bladder cancer (BCa) is one of the most common and expensive urinary system malignancies for its high recurrence and progression rate. In recent years, immense amounts of studies have been carried out to bring a more comprehensive cognition and numerous promising clinic approaches for BCa therapy. The development of innovative enhanced cystoscopy techniques (optical techniques, imaging systems) and tumor biomarkers-based non-invasive urine screening (DNA methylation-based urine test) would dramatically improve the accuracy of tumor detection, reducing the risk of recurrence and progression of BCa. Moreover, intravesical instillation and systemic therapeutic strategies (cocktail therapy, immunotherapy, vaccine therapy, targeted therapy) also provide plentiful measures to break the predicament of BCa. Several exploratory clinical studies, including novel surgical approaches, pharmaceutical compositions, and bladder preservation techniques, emerged continually, which are supposed to be promising candidates for BCa clinical treatment. Here, recent advances and prospects of diagnosis, intravesical or systemic treatment, and novel drug delivery systems for BCa therapy are reviewed in this paper.